Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

298

Sector

Biotechnology & Medical Research

Calendar

2025-02-20 - Q4 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
24-12-09	770.00 kr	+0.06%	118,868
24-12-06	769.50 kr	+1.79%	108,901
24-12-05	756.00 kr	+1.27%	168,003
24-12-04	746.50 kr	+2.26%	143,013
24-12-03	730.00 kr	+0.41%	162,372

Delayed Quote Nasdaq Copenhagen, December 09, 2024 at 11:20 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart ZEALAND-PHARMA-A-S

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

770.00DKK

Average target price

1,015.00DKK

Spread / Average Target

+31.82%

Consensus

Profit revisions

estimates-change-chart ZEALAND-PHARMA-A-S

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ZEALAND-PHARMA-A-S

Company calendar

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-12-09 EST			5-day change	1st Jan Change
770.00 ^DKK	+0.06%		+5.91%	+106.32%

12-09	Swedbank Robur Småbolagsfond Norden decreased 2.03 percent in November - added Netcompany to the portfolio	FW
11-21	Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM

Capitalization	54.4B 7.72B 7.3B 6.77B 6.04B 10.9B 655B 11.94B 84.14B 31.06B 269B 28.99B 28.35B 1,166B	P/E ratio 2024 *	-62x	P/E ratio 2025 *	575x
Enterprise value	47.39B 6.72B 6.36B 5.9B 5.26B 9.5B 571B 10.4B 73.3B 27.06B 234B 25.25B 24.7B 1,016B	EV / Sales 2024 *	125x	EV / Sales 2025 *	26.2x
Free-Float	99.18%	Yield 2024 *	-	Yield 2025 *	-

Swedbank Robur Småbolagsfond Norden decreased 2.03 percent in November - added Netcompany to the portfolio	12-09	FW
Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM	11-21
KBC Securities Initiates Zealand Pharma at Buy	11-20	MT
Zealand Pharma rallies after JP Morgan initiates Overweight rating	11-08	FW
Danske Bank raises Zealand Pharma to 'Keep' (Sell), target price 825 Danish kroner - BN	11-08	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,095 (1,106), reiterates Buy - BN	11-08	FW
JP Morgan initiates coverage of Zealand Pharma with Overweight and target price of DKK 1,100 - BN	11-08	FW
Zealand Pharma A/S, Q3 2024 Earnings Call, Nov 07, 2024	11-07
Zealand Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
Zealand Pharma reports promising results for weight loss drug - BN	11-06	FW
Novo Nordisk share price falls after Viking Therapeutics pill update	11-04	FW
Today's stock recommendations at a glance	10-15	FW
Bank of America initiates coverage of Zealand Pharma with Buy and target price of DKK 1,100 - BN	10-15	FW

KBC Securities Initiates Zealand Pharma at Buy	11-20	MT
Zealand Pharma rallies after JP Morgan initiates Overweight rating	11-08	FW
Danske Bank raises Zealand Pharma to 'Keep' (Sell), target price 825 Danish kroner - BN	11-08	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,095 (1,106), reiterates Buy - BN	11-08	FW
JP Morgan initiates coverage of Zealand Pharma with Overweight and target price of DKK 1,100 - BN	11-08	FW

Zealand Pharma A/S Stock

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Valuation: Zealand Pharma A/S

Chart: Zealand Pharma A/S

Latest news: Zealand Pharma A/S

Last Transcript: Zealand Pharma A/S

Analysts' recommendations: Zealand Pharma A/S

Press Releases: Zealand Pharma A/S

News in other languages: Zealand Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Zealand Pharma A/S

ETFs: Zealand Pharma A/S

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Zealand Pharma to participate in the Jefferies London Healthcare Conference	11-13	GL
Zealand Pharma to participate in the Jefferies London Healthcare Conference	11-13	AQ
Zealand Pharma A/S - Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons	11-12	AQ
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	11-11	GL
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	11-11	AQ

Actualización de las fuertes variaciones del día: Continental anuncia buenas noticias; temores en Bayer	10-09
Les actions en mouvement : Continental annonce de bonnes nouvelles ; craintes chez Bayer	10-09
Chassez la géopolitique, elle revient au galop	10-02
Avis d'analystes du jour : Kering, STMicro, Stellantis, Worldline, TotalEnergies, Unibail, Richemont...	10-02
OPINIONI DEGLI ANALISTI DEL GIORNO: Brembo, Buzzi, Eni, STMicro, Stellantis, Generali, Moncler, Stellantis, Telecom Italia...	10-02

1 day	+0.06%
1 week	+5.91%
Current month	+5.48%
1 month	-9.09%
3 months	-10.26%
6 months	+18.46%
Current year	+106.32%

Director	Title	Age	Since
Adam Sinding Steensberg CEO	Chief Executive Officer	50	2022-03-29
Henriette Wennicke DFI	Director of Finance/CFO	-	2022-10-31
David M. Kendall CTO	Chief Tech/Sci/R&D Officer	62	2022-06-01

Manager	Title	Age	Since
Alf Gunnar Martin Nicklasson CHM	Chairman	69	-
Kirsten Drejer BRD	Director/Board Member	68	2018-04-18
Bernadette Connaughton BRD	Director/Board Member	65	2019-04-03

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ZEALAND PHARMA A/S	+0.06%	+5.91%	+116.29%	+462.04%	7.71B
VERTEX PHARMACEUTICALS INCORPORATED	+2.57%	+1.77%	+35.36%	+127.43%	119B
REGENERON PHARMACEUTICALS, INC.	+1.29%	+3.37%	-6.21%	+18.37%	83.7B
ARGENX SE	-0.95%	-0.78%	+38.02%	+116.18%	37.69B
BIONTECH SE	-0.74%	+3.09%	+16.81%	-57.49%	29.18B
BEIGENE, LTD.	+0.97%	+0.91%	+18.64%	-32.06%	21.85B
WUXI APPTEC CO., LTD.	+6.81%	+15.15%	-22.39%	-58.29%	21.71B
GENMAB A/S	+0.81%	+0.64%	-30.66%	-40.87%	14.53B
SUMMIT THERAPEUTICS INC.	+0.65%	+0.92%	+752.05%	+280.82%	13.67B
INSMED INCORPORATED	-3.49%	+0.48%	+160.26%	+170.32%	13.49B
Average	+0.80%	+2.97%	+107.82%	+98.64%	36.25B
Weighted average by Cap.	+1.38%	+2.65%	+50.83%	+73.21%

	2024 *	2025 *
Net sales	378M 53.59M 50.65M 46.99M 41.9M 75.68M 4.55B 82.91M 584M 216M 1.87B 201M 197M 8.09B	1.77B 251M 237M 220M 196M 355M 21.32B 389M 2.74B 1.01B 8.75B 943M 923M 37.94B
Net income	-774M -110M -104M -96.35M -85.92M -155M -9.32B -170M -1.2B -442M -3.83B -413M -404M -16.6B	226M 32.01M 30.26M 28.07M 25.03M 45.21M 2.72B 49.53M 349M 129M 1.11B 120M 118M 4.84B
Net Debt	-7.01B -994M -940M -872M -778M -1.4B -84.38B -1.54B -10.84B -4B -34.62B -3.73B -3.65B -150B	-8.02B -1.14B -1.08B -997M -889M -1.61B -96.53B -1.76B -12.4B -4.58B -39.61B -4.27B -4.18B -172B